Overview

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Status:
Completed
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2b, Randomized, Double-blind, Placebo-controlled, multiple dose study of PTI-125 in mild-to-moderate Alzheimer's disease patients.
Phase:
Phase 2
Details
Lead Sponsor:
Cassava Sciences, Inc.
Collaborator:
National Institute on Aging (NIA)